Amplia Therapeutics Ltd (ATX) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.028x

Based on the latest financial reports, Amplia Therapeutics Ltd (ATX) has a cash flow conversion efficiency ratio of -0.028x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.09 Million ≈ $-768.53K USD) by net assets (AU$39.47 Million ≈ $27.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ATX equity to assets ratio to measure how much of total assets are equity-financed.

Amplia Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2010–2026)

This chart illustrates how Amplia Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore ATX operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.

Amplia Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Amplia Therapeutics Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Univastu India Limited NSE:UNIVASTU	-0.089x
Budi Starch & Sweetener Tbk JK:BUDI	0.018x
Pangaea Oncology S.A. MC:PANG	-0.060x
Wisekey International Holding AG SW:WIHN	-0.070x
1895 of Wisconsin Inc Bancorp NASDAQ:BCOW	0.003x
UY Scuti Acquisition Corp. NASDAQ:UYSC	N/A
Bridgford Foods Corporation NASDAQ:BRID	-0.055x
LondonMetric Property Plc LSE:LMP	0.025x

Annual Cash Flow Conversion Efficiency for Amplia Therapeutics Ltd (2010–2026)

The table below shows the annual cash flow conversion efficiency of Amplia Therapeutics Ltd from 2010 to 2026. For the full company profile with market capitalisation and key ratios, see market value of Amplia Therapeutics Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2026-03-31	AU$39.47 Million ≈ $27.93 Million	AU$-8.73 Million ≈ $-6.18 Million	-0.221x	+32.44%
2025-03-31	AU$21.02 Million ≈ $14.88 Million	AU$-6.89 Million ≈ $-4.87 Million	-0.328x	+27.06%
2024-03-31	AU$11.42 Million ≈ $8.08 Million	AU$-5.13 Million ≈ $-3.63 Million	-0.449x	-34.42%
2023-03-31	AU$15.84 Million ≈ $11.20 Million	AU$-5.29 Million ≈ $-3.74 Million	-0.334x	-65.79%
2022-03-31	AU$21.85 Million ≈ $15.46 Million	AU$-4.40 Million ≈ $-3.11 Million	-0.201x	+28.56%
2021-03-31	AU$10.34 Million ≈ $7.32 Million	AU$-2.92 Million ≈ $-2.06 Million	-0.282x	-16.24%
2020-03-31	AU$8.61 Million ≈ $6.09 Million	AU$-2.09 Million ≈ $-1.48 Million	-0.243x	-112.92%
2019-03-31	AU$8.66 Million ≈ $6.13 Million	AU$-987.35K ≈ $-698.61K	-0.114x	+92.41%
2018-03-31	AU$2.36 Million ≈ $1.67 Million	AU$-3.55 Million ≈ $-2.51 Million	-1.501x	-61.48%
2017-03-31	AU$6.63 Million ≈ $4.69 Million	AU$-6.16 Million ≈ $-4.36 Million	-0.930x	+21.06%
2016-03-31	AU$4.00 Million ≈ $2.83 Million	AU$-4.71 Million ≈ $-3.34 Million	-1.178x	-44.06%
2015-03-31	AU$4.87 Million ≈ $3.44 Million	AU$-3.98 Million ≈ $-2.81 Million	-0.817x	-397.85%
2014-03-31	AU$9.77 Million ≈ $6.91 Million	AU$-1.60 Million ≈ $-1.14 Million	-0.164x	-5.13%
2013-03-31	AU$11.23 Million ≈ $7.95 Million	AU$-1.75 Million ≈ $-1.24 Million	-0.156x	+60.77%
2012-03-31	AU$3.19 Million ≈ $2.26 Million	AU$-1.27 Million ≈ $-899.95K	-0.398x	-50.85%
2011-03-31	AU$6.07 Million ≈ $4.30 Million	AU$-1.60 Million ≈ $-1.13 Million	-0.264x	+22.54%
2010-03-31	AU$5.98 Million ≈ $4.23 Million	AU$-2.04 Million ≈ $-1.44 Million	-0.341x	--

About Amplia Therapeutics Ltd

AU:ATX Australia Biotechnology

Market Cap

$56.30 Million

AU$79.56 Million AUD

Market Cap Rank

#21425 Global

#737 in Australia

Share Price

AU$0.16

Change (1 day)

+14.81%

52-Week Range

AU$0.11 - AU$0.27

All Time High

AU$16.20